Pt Prodia Widyahusada Tbk · IDX:PRDA

Pt Prodia Widyahusada Tbk — Q1 2022 Earnings Presentation

35 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2022

  1. Slide 1: 1Q2022 Results Update

    x 1Q2022 Results Update

  2. Slide 2: Disclaimer

    DISCLAIMER This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie

  3. Slide 3: List of Figures

    LIST OF FIGURES Corporate Overview 04 Indonesia Healthcare Market 18 Financial Update 31 Global Trend in Diagnostic Lab Company Highlight 05 19 Gross Profit and Net Income 32 Market Company History 06 Growth Strategy 20 COGS and OPEX 33 Investment Highlight 07 Leader in Next Gen Technology 21 Financ

  4. Slide 4: Corporate Overview

    1 CORPORATE OVERVIEW 4

  5. Slide 5: Company Highlight

    • More than 49 years IDR 556.1 Billion experience in Clinical Lab Industry since 1973 1Q2022 Revenue (-11.1% yoy; 3yrs CAGR +11.7%) • Has the most recognized Brand in Indonesia >777K • Largest private 1Q2022 Visit (-6.7% yoy; 3yrs CAGR +8.6%) independent clinical lab chain by size of network and rev

  6. Slide 6: Strong Track Record in Clinical Laboratory Testing

    Strong Track Record in Clinical Laboratory Testing • Establishment of Prodia Became the first  Established professional Partnerships National Referral Lab,  Established clinical laboratory management team with National the first Indonesian lab Prodia ChildLab in Indonesia to  Scholarships given t

  7. Slide 7: Investment Highlight

    2 INVESTMENT HIGHLIGHT 7

  8. Slide 8: Largest Network & Market Share in Independent Clinical Lab Industry

    Largest Network & Market Share in Independent Clinical Lab Industry Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2019 & 2020) (Billion IDR) 3YRS CAGR 7.4% 39.2% 39.5% 4,874 3YRS CAGR 4,222 4,551 8.2% 26.9% 2019 27.8% 2020 1,600 1,744 1,873 33.9% 32.7% 2018 2019

  9. Slide 9: Strong Operational Track Record

    Strong Operational Track Record VISITS REVENUE CAGR CAGR 7.7% 14.3% Prodia has generated continuous revenue growth 2016 2017 2018 2019 2020 2021 2016 2017 2018 2019 2020 2021 and increasing number of visits that supported REVENUE PER VISIT Company’s profitability EBITDA CAGR 6.1% CAGR 34.4% 9 2016 2

  10. Slide 10: Comprehensive Service Offering with Multiple Customer Segments

    Comprehensive Service Offering with Multiple Customer Segments Routine Testing Non-Laboratory Testing Specialty Clinics One-stop shop, offering the most Esoteric Testing Referral Lab Services Doctor Consultation comprehensive Predictive, Preventive, General Medical Preventive Treatment range of clin

  11. Slide 11: Scalable Hub and Spoke Business Model

    Scalable Hub and Spoke Business Model 4 Referral Labs in Jakarta, Significant Surabaya, Medan, Makassar Economies of Scale Achieved “Hub and spoke” model offers scalable platform reducing Centralized information Prodia Clinical Labs, Prodia Referral with integrated IT turnaround time and cost Hospit

  12. Slide 12: Strong Relationship with Medical Community

    Strong Relationship with Medical Community Strong relationships through the work of more Introduced new tests, such as NIPT ProSafe, Amino Acid Profile, than 500 Marketing and Laboratory Fatty Acid Profile, CArisk, DIArisk, Liquid biopsy EGFR Mutation, New Information Service personnel Born Screenin

  13. Slide 13: One of the Largest Digital Healthcare Platform in Indonesia

    One of the Largest Digital Healthcare Platform in Indonesia Walk-in Apps Doctor Referral Apps Prodia Mobile Prodia Mobile for Doctor More than 944K Launched in April 2022 downloaders • Online Referral • Online registration • Online Chat • Online Payment 152.9% Patient’s Growth • Online Results • Onl

  14. Slide 14: Experienced Senior Leadership and Management Team

    Experienced Senior Leadership and Management Team Professional Management Team with Strong Track Record in Delivering Superior Growth and Innovation Years of Years of Years of Years of Years of 48 Experience 48 Experience 38 Experience 30 Experience 30 Experience Andi Gunawan Endang Kemal Imam Keri

  15. Slide 15: Shareholder Composition

    Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public 57% 18% 25% Contract Research, therapy Distributor for Research and banking of healthcare Organization stem cell products PT Prodia Widyahusada Tbk Occupational In Vitro Health Diagnostics Nationwide Outlet Network across Indonesia

  16. Slide 16: Market Overview & Growth Strategy

    3 MARKET OVERVIEW & GROWTH STRATEGY 16

  17. Slide 17: Indonesia Economic Outlook

    Indonesia Economic Outlook 4.5% – 5.4% Indonesia’s GDP Growth Projection for 2022 Indonesia’s economic recovery and improvement in 2022 will GDP Growth Projection 2022 be supported by the Indonesia World stability to control Indonesia’s Govt’ 4.5% - 5.3% N/A COVID-19 pandemic, World Bank 5.2% 4.1% r

  18. Slide 18: Indonesia Healthcare Market

    Indonesia Healthcare Market Indonesia Healthcare Market Indonesia Digital Healthcare Market (IDR Trillion) (IDR Trillion) 700.0 624.2 50.0 45.5 585.3 600.0 548.3 509.1 40.0 462.7 435.1 472.4 500.0 423.3 435.0 28.0 400.0 30.0 300.0 20.0 17.2 200.0 10.6 8.1 10.0 3.9 5.9 100.0 0.9 2.3 - - 2017 2018 201

  19. Slide 19: Global Trend in Diagnostic Lab Market

    Global Trend in Diagnostic Lab Market 1 2 3 4 Creating Digital Strategic Customer Centric Development of Ecosystem Partnership and Model testing technology Collaboration and AI Healthcare Platform B2B Business Expansion Digital Customer Journey Preventive Genomics Electronic Health Record Market Con

  20. Slide 20: Company's Growth Strategy

    Company’s Growth Strategy Strengthen digital capabilities to Expand our presence and enable business growth grow our network of outlets in both physical and digital Develop data & analytics channel in Indonesia Near- capabilities to create business values A term Upgrade existing clinical Enhance int

  21. Slide 21: Leader in Next Generation Technology

    Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Advance Pathology Immunology Laboratory Laboratory Personalized Treatment The Concept of Precision Me

  22. Slide 22: Our Response to Business Landscape

    Our Response to Business Landscape • Upgrade Prodia apps • Wellness Package • Prodia Mobile for Doctor • Genomic Tests • ProdiaLink for External Referral • Ethos – HS platform • Prodia in Your Car Lab Market: Digital Service Development Product and Lab Testing Innovation New Players Coming • License

  23. Slide 23: Prodia Sustainable Action Plan

    Prodia Sustainable Action Plan Prodia Sustainable Action Plan is an initiative and effort made by Prodia in order to achieve sustainable business growth so as to create added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment.

  24. Slide 24: Business Update

    4 BUSINESS UPDATE 24

  25. Slide 25: Deliver Solution for Customer Needs

    DELIVER SOLUTION FOR CUSTOMER NEEDS Respond to People Behavior Changing and Customer’s Voice Services & Lab Facilities • Safety, Quality & Cleanliness Product Innovation of Our Lab/Facilities/Staffs • Complete Testing from Routine to Esoteric • Prodia Mobile Test, Genomics Testing • Home/Office Serv

  26. Slide 26: Customer Centric Model: New Innovation & Enhancement

    Customer Centric Model Prodia in your Car New Innovation & Enhancement Service Prodia Home Customer Service Centric Tele-Consultation Tele-Radiology • General Practitioners • Clinical Pathologists Tele-Health* • Internist ProdiaLink • Clinical Nutritionist • Sport Medicine

  27. Slide 27: Digital Transformation to Fulfill Customer Needs

    Digital Transformation to Fulfill Customer Needs Prodia Mobile apps provides online registration/booking, online payment, online results, chat with doctors, and home service booking. > > Prodia has enhanced its digital platform services New Prodia Mobile Ver. 3.3.0 – Updated in April 2022 27

  28. Slide 28: Digital Diagnostic Partner for Doctors

    Digital Diagnostic Partner for Doctors Prodia Mobile for Doctor apps assist doctors to create testing referral to all Prodia’s Lab Services, provides live chat and manage their patient’s online health report. Launched in April 2022 28

  29. Slide 29: Outlet Development

    Outlet Development 2016-2022 Outlet Development 2022 Outlet Development Target 1-2 20 259 283 292 287 267 259 255 Clinical Labs POC Outlets 5 7 4** 4** 4** 2 4** 11 14 14 12 9 9 8 128 122 1-2 1 118 130 108 98 95 Hospital Labs Specialty Clinic 129 136 143 147* 148* 148* 148* “Prodia not only focus to

  30. Slide 30: 1Q2022 Revenue (Unaudited)

    1Q2022 Revenue (Unaudited) Revenue Quarterly Revenue in IDR Billion in IDR Billion 2022 2021 2020 • Revenue slowing FY16-FY21 CAGR +14.3% 1Q17-1Q22 CAGR +10.9% down by -11.1% yoy, 2019 2018 2017 due to healthcare 2016 market 3Q21, normalization along 752 with the stable 2,652 1Q21, 4Q21, pandemic si

  31. Slide 31: Financial Update

    5 FINANCIAL UPDATE 31

  32. Slide 32: 1Q2022 Gross Profit & Net Income (Unaudited)

    1Q2022 Gross Profit & Net Income (Unaudited) Gross Profit (in IDR Billion) Net Income (in IDR Billion) FY16-FY21 CAGR +15.5% 1Q17-1Q22 CAGR +11.6% FY16-FY21 CAGR +47.8% 1Q17-1Q22 CAGR +26.6% 1Q21-1Q22 1Q21-1Q22 growth -14.7% growth -33.7% 621.6 62.3% 25.4% 61.6% 23.4% 59.7% 59.1% 59.8% 18.9% 58.4% 5

  33. Slide 33: 1Q2022 COGS & OPEX (Unaudited)

    1Q2022 COGS & OPEX (Unaudited) COGS (in IDR Billion) OPEX (in IDR Billion) FY16-FY21 CAGR +12.5% 1Q17-1Q22 CAGR +9.9% FY16-FY21 CAGR +5.4% 1Q17-1Q22 CAGR +4.9% 1Q21-1Q22 1,000 1Q21-1Q22 878 70 1,019.6 growth -5.1% 827 growth +1.6% 49.0% 770 746 42 65 800 676 713 50 827.2 146 47.0% 46 30 60 703.3 39

  34. Slide 34: 1Q2022 Financial Summary (Unaudited)

    1Q2022 Financial Summary (Unaudited) (in IDR Bn) 1Q2022 1Q2021 Change (in IDR Bn) 1Q2022 1Q2021 Change Revenue 556.1 625.5 -11.1% Total Asset 2,834.3 2,401.4 +18.0% Gross Profit 332.4 389.8 -14.7% Total Equity 2,350.7 1,953.5 +20.3% EBIT 125.3 192.9 -35.0% EBT 132.7 201.1 -34.0% Net Income 105.2 158

  35. Slide 35: Thank You!

    THANK YOU! For more information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id 35

PT Prodia Widyahusada — Q1 2022 Earnings Presentation on 6ix